Ultrathin bronchoscopy and cryobiopsy in diagnosing peripheral pulmonary lesions: Another tool in the toolbox

Ing, Alvin; Saghaie, Tajalli

doi:10.1111/resp.14402

Cited by 1 publication

(1 citation statement)

References 17 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome these limitations, our group has utilized cryobiopsy-derived specimens for LCO culture for the first time. Cryobiopsy was recently introduced in lung biopsy to diagnose interstitial lung disease or lung cancer [22,23,42,43]. With cryobiopsy, we obtained even larger lung cancer tissues from patients with all stages of lung cancer and both central and peripheral lesions.…”

Section: Discussionmentioning

confidence: 99%

Cryobiopsy: A Breakthrough Strategy for Clinical Utilization of Lung Cancer Organoids

Park

Lee

Kim

et al. 2023

Cells

View full text Add to dashboard Cite

One major challenge associated with lung cancer organoids (LCOs) is their predominant derivation from surgical specimens of patients with early-stage lung cancer. However, patients with advanced lung cancer, who are in need of chemotherapy, often cannot undergo surgery. Therefore, there is an urgent need to successfully generate LCOs from biopsy specimens. Conventional lung biopsy techniques, such as transthoracic needle biopsy and forceps biopsy, only yield small amounts of lung tissue, resulting in a low success rate for culturing LCOs from biopsy samples. Furthermore, potential complications, like bleeding and pneumothorax, make it difficult to obtain sufficient tissue. Another critical issue is the overgrowth of normal lung cells in later passages of LCO culture, and the optimal culture conditions for LCOs are yet to be determined. To address these limitations, we attempted to create LCOs from cryobiopsy specimens obtained from patients with lung cancer (n = 113). Overall, the initial success rate of establishing LCOs from cryobiopsy samples was 40.7% (n = 46). Transbronchial cryobiopsy enables the retrieval of significantly larger amounts of lung tissue than bronchoscopic forceps biopsy. Additionally, cryobiopsy can be employed for peripheral lesions, and it is aided via radial endobronchial ultrasonography. This study significantly improved the success rate of LCO culture and demonstrated that the LCOs retained characteristics that resembled the primary tumors. Single-cell RNA sequencing confirmed high cancer cell purity in early passages of LCOs derived from patients with advanced lung cancer. Furthermore, the three-dimensional structure and intracellular components of LCOs were characterized using three-dimensional holotomography. Finally, drug screening was performed using a specialized micropillar culture system with cryobiopsy-derived LCOs. LCOs derived from cryobiopsy specimens offer a promising solution to the critical limitations of conventional LCOs. Cryobiopsy can be applied to patients with lung cancer at all stages, including those with peripheral lesions, and can provide sufficient cells for LCO generation. Therefore, we anticipate that cryobiopsy will serve as a breakthrough strategy for the clinical application of LCOs in all stages of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%